Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus dacarbazine in metastatic or unresectable malignant melanoma
2012-001020-35Phase 2Terminated
- Sponsor
- Helse Bergen
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in melanoma, sponsored by Helse Bergen. Started Sep 2012; status: terminated.
02
Drugs
bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-001020-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001020-35.